Radiotherapeutics remain in the deal-making frame
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
Point’s path leads to a Spac
The radiopharmaceutical researcher was negotiating a series B funding round when it got an offer from a Spac that it could not refuse.
As the heat rises, Clovis turns to radionuclides
The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.
